International Journal of Science and Research (IJSR)
ISSN: 2319-7064
SJIF (2022): 7.942

An Assessment Article on the Cure of Sarcopenia and its Association with type 2 Diabetes in the Elderly

Micah Isaac Anand W

JSS College of Pharmacy, Ooty

Abstract: ***Insulin resistance is one of the most frequent absconds within the pathogenesis of type 2 diabetes. Sort 2 Diabetes Mellitus (T2DM), one of the foremost common metabolic clutters, is caused by a combination of two essential components: imperfect insulin emission by pancreatic - cells and the failure of insulin - sensitive tissues to reply suitably to insulin. Sarcopenia, characterised by the misfortune of skeletal muscle mass and quality, has become a common trademark of maturing and numerous incessant maladies. Diabetes mellitus patients have the next predominance of sarcopenia, which enormously irritates the metabolic unsettling influence and compromises the treatment reaction. Preclinical and clinical studies have shown differential impacts of anti - diabetic drugs on skeletal muscle mass, quality, and execution, highlighting the importance of a sound, accommodating regimen from the point of view of sarcopenia danger. The coexistence of these circumstances compounds the worries of elderly patients. In this paper, we audit the most effective measures for the avoidance and administration of sarcopenia and/or slightness in elderly patients with T2DM.***

Keywords: Type 2 diabetes mellitus, sarcopenia, weight loss in type 2 diabetes patient, anti - diabetic drugs induced sarcopenia, pharmacotherapy of type 2 diabetes with sarcopenia

1. Introduction

Insulin resistance may be a hallmark of T2DM and result from poor glycemic management, which may have an impact on sarcopenia - related components [1]. The degenerative loss of skeletal muscle mass (SMM), quality, and quantity that occurs during normal ageing is known as skeletal muscle wasting (sarcopenia). For the treatment of T2DM, we now maintain a sizable armament stockpile [2]. Since glucose control is thought to be less rigorous in this group of more experienced patients, restorative guidelines vary depending on individual understanding. Additionally, the multiple comorbidities, like sarcopenia and slightness, that these patients frequently display have an impact on the helpfulness of the elderly population relative to that of the younger population. A comprehensive assessment of the health status of older adults with T2DM is essential to improving quality of life, protecting the usefulness of treatment, and maintaining a strategic distance from complications, primarily hypoglycemia [3, 4].

2. Insulin Resistance

The generation and effectiveness of insulin decrease in elderly and stout individuals. In the interim, corpulence is related to a matter of opinion review aggravation: the expanded generation and emission of diverse provocative components counting TNF - and IL - 6 tweak insulin affectability by modifying a few key steps within the affront flagging pathway, which is mindful of the consequent resistance [5 - 7]. Considerations have explained that insulin resistance is fundamental for protein anabolism and hence directly concerns muscle fibre decay [8]. Corpulent people with insulin resistance have the next rate of muscle catabolism, which has been proven by the fact that leg muscle quality and quality diminish unmistakably in more seasoned diabetics [9]. Subsequently, insulin resistance is included in destitute muscle mass and muscle quality, dynamically coming about in SO. Moreover, insulin resistance is connected to mitochondrial brokenness as well. A down - regulation of qualities including mitochondrial proteins decreases mitochondrial substance, which has been found in insulin - safe states [10, 11], expanding the aggregation of fat in muscle and liver. Thus, the misfortune of muscle quality and the pick - up of fat that characterise SO are attributed to insulin resistance [12].

3. Hormonal Changes

As an endocrine organ, the muscle can deliver an assortment of myokines, such as myostatin and irisin. It is accepted that myostatin represses muscle cell development and separation, and irisin invigorates the increment of muscle mass [13, 14]. Be that as it may, a few researchers have reported that the substance myostatin is upregulated, whereas irisin is down regulated, in sarcopenia [15]. At the same time, the increment in myostatin and diminishment in irisin are firmly related to the destitute browning response of white fat, lessening vitality use and activating fat pick - up [16]. Inevitably, the crosstalk between muscle and fat leads to muscle harm, evoking SO. Other hormones, including insulin - like development factors - 1 (IGF - 1), development hormone, testosterone, and oestrogen, also direct the anabolic and catabolic movements in muscle [17]. The lessening of IGF - 1 is accompanied by the down regulation of irisin [16], and the high level of free fatty acids in corpulent individuals represses both IGF - 1 and development hormone [19], which brings down the mass and quality of muscle, driving up muscle impedance and hence SO [20]. Additionally, testosterone and oestrogen are basic for muscle wellbeing [18], but the generation of these hormones decreases normally with maturation. Subsequently, muscle mass and quality degrade with diminished testosterone and oestrogen concentrations [21]. Hence, abnormal hormonal changes with age compound SO.

Sarcopenia and Feebleness in More Seasoned T2DM:

Patients: The prevalence of T2DM among the elderly is increasing. These patients more often than not show different comorbidities; a few of them are related to the common advancement of diabetes (neuropathy, nephropathy, retinopathy, etc.), and other substances are free of the advancement of diabetes, in spite of the fact that they may be related. Feebleness is one of them, a standardised phenotype in more seasoned adults with a prescient legitimacy for antagonistic results in geriatric patients. It is a rising worldwide burden for wellbeing, with imperative suggestions for clinical honed and open wellbeing [22]. Diabetes mellitus is characterised by a state of persistent hyperglycemia related to modifications in the carbohydrate, fat, and protein digestion systems, which lead to a shortage of affront emission and affront resistance, which are included in muscle protein misfortune. Lifted levels of cytokines, such as TNF, IL - 1, IL - 5, or IL - 6, common in patients with T2DM, can affront resistance. In expansion, the regular mitochondrial brokenness in diabetic patients favours changed lipid oxidation, lifted lipid in muscle cells, and affront resistance, which increments the advancement of feebleness and sarcopenia [23]. Additionally, misfortune of muscle mass auxiliary to sarcopenia and age too leads to metabolic dysregulation resulting in decreased affront affectability, modified oxidative protections, and diminished mitochondrial function. Age - related modifications within the hypothalamus - pituitary - testicular, hypothalamus - pituitary - adrenal, and insulin - like development figures IGF - 1 and sort 1 IGF receptor (IGFR1r) tomahawks increment the misfortune of muscle quality [24]. Testosterone and IGF - 1, hormones included in muscle protein amalgamation, are diminished in patients with T2DM. In expansion, visit modifications within the adipocyte hormones leptin and ghrelin in more seasoned age too meddle adversely with plasma affront levels [25]. All these pathophysiological changes clarify how diabetes mellitus, advanced age, slightness, and sarcopenia are interrelated. In order to analyse persistent slightness, Fried's slightness criteria are broadly utilised [26]. According to these criteria, the determination of slightness is built up on the off chance that the understanding meets three of the following things: inadvertent weight misfortune, weariness, muscle shortcoming, engine gradualness, and moo activity. In addition, T2DM could be a chance for the advancement of slightness. Subsequently, wholesome instruction and physical action to control glycemic levels are successful in maintaining useful independence [27]. Feebleness is determined by hereditary, epigenetic, and natural components, with affront resistance, arteriosclerosis, brain white matter injuries, inveterate aggravation, oxidative stretch, or mitochondrial brokenness being a few of the most common instruments of feebleness in more seasoned adults with T2DM [28]. Due to the tall predominance of T2DM in slightly more seasoned patients and considering the complexity of T2DM and the burden of related comorbidities, it is critical to recognise this bunch of powerless patients who require near follow - up with the point to execute restorative measures and intercession techniques to maintain a strategic distance from an assist disintegration in utilitarian status [29].

In addition, slightness is related to mortality and hospitalisation in patients with diabetes. Coincidental falls are one of the most common factors linking feebleness with hospitalisation. Delicate patients have an increased chance of falling [30]. Falls are too common in diabetic patients, and circumstances such as hypoglycemia do indeed contribute more to this relationship [31]. It is well known that both mild and diabetic patients have more complications and a more regrettable outlook amid healing centre confirmations. Hence, it is enormously imperative to anticipate this sort of complication in mild and diabetic patients [32].

Increasing consideration is being paid to sarcopenia due to its solid effect on the quality of life of elderly patients with T2DM [33]. Sarcopenia is characterised as a muscle malady (muscle disappointment) in connection to unfavourable muscle changes over the lifetime, being common in the elderly and centred on moo muscle quality as the most characteristic. There are diverse ways to identify moo muscle amount and quality to affirm the sarcopenia determination [34]. The three primary conditions within the differential diagnosis of sarcopenia are lack of healthy sustenance, cachexia, and feebleness, in spite of the fact that they frequently coexist [35].

Sarcopenia has a higher predominance in patients with T2DM (predominance extending from 5 to 50%) than in patients without T2DM [36]. Sarcopenia related to feebleness and the microvascular and macrovascular complications of diabetes are developing as an important category of complications driving incapacity, reliance, and expanded mortality [33]. All this has a high impact on the quality of life of patients, influencing their physical and psychosocial wellbeing and consequently becoming a critical open wellbeing programme [37]. Quality of life is the most objective in more seasoned patients; hence, early discovery of slightness and sarcopenia are key perspectives within the administration of more seasoned patients in general and diabetics inparticular [38].

T2DM, sarcopenia, and slightness produce unremitting systemic proinflammatory states that deliver immunological changes within the safe frameworks of patients. Immuno - senescence has a more regrettable clinical course. It favours the procurement of irresistible maladies and destitute reactions to immunisation, among others [39]. On the other hand, the proinflammatory state favours the advancement of tissue damage, sarcopenia, and feebleness. All these circumstances, interwoven with each other, obstruct the administration of these patients [40, 41]. Another complication commonly observed in patients with T2DM and sarcopenia is sarcopenic corpulence, characterised by the concomitant nearness of sarcopenia and weight. The prevalence of sarcopenic corpulence is higher in diabetic patients. Physical exercise and a healthy diet are the most effective treatments for sarcopenic weight loss, followed by antidiabetic drugs separately endorsed by clinicians for the treatment of T2DM [42].

4. Impacts of anti - diabetic drugs on the muscle

To gain an efficient understanding of the influence of commonly used anti - diabetic drugs on sarcopenia, we performed an exact examination of preclinical and clinical considerations in MEDLINE, using the following words: "sarcopenia' OR 'skeletal muscle mass' OR 'muscle mass' OR 'lean mass' OR 'body composition' OR 'muscle quality" AND "antidiabetic drugs' OR 'glucose - lowering drugs' OR 'metformin' OR 'thiazolidinediones' OR 'pioglitazone' OR 'rosiglitazone' OR 'sulfonylureas' OR 'DPP - 4 inhibitors' OR 'GLP - 1 receptor agonists' OR 'SGLT2 inhibitors' OR 'insulin" Most of what comes out of specialist clinical trials has been nitty - gritty for a long time.

4.1 Insulin

Insulin treatment has been established for the clinical progress of glucose - lowering operators [43]. In addition to its effect on glycaemic homeostasis, attack might be a solid stimulatory factor for muscle protein union. The rebellious means by which insulin makes strides in muscle protein anabolism are not, be that as it may, completely caught on, in showing disdain towards the truth that they to an incredible degree incorporate extended beginnings of mRNA elucidation, microvascular selection, the blood stream, amino destructive movement to skeletal muscle, and diminished protein debasement [44]. In any case, within the setting of attack resistance, endothelial brokenness, and diabetic microangiopathy, the positive effect of insulin on muscle mass may be compromised in T2DM people.

Indeed, diminishment in endogenous insulin outflow is a defiance chance figure of sarcopenia in men with T2DM [45]. In past studies in Japanese patients, it has appeared that attack treatment might choke the decrease of muscle quality inside the lower limits but not inside the upper extremities, [46] supporting the clinical usage of insulin to decrease sarcopenia risk in T2DM patients. As of late, a longitudinal study of insult treatment with changes in muscle parameters uncovered that insulin protected muscle mass but not muscle work as assessed by hand - hold quality [47]. Be that as it may, it is imperative that a few early clinical studies almost dissecting attack treatment and body composition have demonstrated that insulin - induced weight gain is attributed to an increment in both fat and fat - free mass (FFM) [48 - 50]. Customarily, in patients with T2DM, weight gain to an extraordinary degree reflects an increase in trunk FM. In this way, the effect of insult treatment on skeletal mass may vary depending on the sort of diabetes, and it remains to bedecided whether the incline to the central weight to some degree offsets other benefits of attack treatment in T2DM.

4.2 Sulfonylureas and glinides

Sulfonylureas and glinides are affront discharge fortifying drugs that work by means of restraint of the ATP - sensitive K+ (KATP) channel. The KATP channel is an octameric complex composed of deep - down redressing K+ channels (Kir6.1 and Kir6.2) and sulfonylurea receptor subunits (SUR1, SUR2A, and SUR2B) in a tissue - dependent manner [51]. In skeletal muscle, the Kir6.2 and SUR2A subunits constitute the most complex KATP channel complex, whereas other SUR subunits communicate with totally different sorts of muscle [52]. Preclinical information has connected KATP channel blockers to muscle decay. For example, Tricarico et al. found that down - regulation of SUR1/Kir6.2 and conceivably other KATP channel subtypes led to atrophic flagging in slow - twitch and fast - twitch skeletal muscles in rats [53]. In vitro tests showed that down - regulation of the KATP channel actuated by a counter - acting agent focusing on the pyruvate kinase, which is practically coupled to the Kir6.2 subunit, results in skeletal muscle fibre decay and cell death [54]. Moreover, glibenclamide was found to improve caspase - 3 movement in slow - twitch muscle and diminish the proportion of protein concentration to muscle weight [53]. Given the hint relationship between the KATP channel and skeletal muscle homeostasis, the suppressive impact of sulfonylureas and glinides on the KATP channel raises the plausibility that these drugs may have an unfavourable impact on SMM and work. A past database search about examining atrophy - related signals related to the utilisation of sulfonylureas and glinides detailed that, in an 8 - month period, muscle decay was found in 0.27% of the glibenclamide reports, 12 times the rate of the overall reports for all drugs not related to sulfonylureas orglinides [55]. It is recommended that drug - induced decay be clarified by the KATP channel bar and the upgrade of the mitochondrial succinic dehydrogenase movement. As of late, a post - hoc investigation appeared to indicate that 24 - week treatment with glimepiride actuated no critical diminishment in fat and bone - free mass (FBFM) in T2DM patients [56]. These discoveries propose that drugs such as glibenclamide and glimepiride ought to be utilised with great caution in patients with a high penchant for sarcopenia.

4.3 Metformin

As the first - line verbal medicine for T2DM, metformin makes strides against resistance and hyperinsulinemia through numerous instruments, which transcendently include the actuation of the AMP - activated protein kinase (AMPK) flagging pathway [57]. The metabolic benefits of metformin are attributed to activities on different tissues, including the liver, digestive system, fat tissue, and muscle.36 The glycaemic diminishment amid metformin treatment is more regularly associated with weight misfortune, and numerous studies have reliably related long - term metformin utilisation with diminished FM [58 - 60]. In any case, metformin's effect on incline mass in T2DM patients remains debatable. Musi et al. illustrated that FFM did not alter altogether after metformin treatment for 10 weeks [61]. A comparative result was also found in a clinical study of 29 members with recently analysed T2DM over a period of up to 6 months [60]. In a multicentre longitudinal cohort study about selecting walking men matured over 65 for a long time, it appeared that men treated with metformin had essentially less add - up to or appendicular incline mass misfortune than those with untreated diabetes or diabetes treated without metformin [62]. The creators conjectured that this impact may be clarified by up - regulation of peroxisome proliferator - activated receptor - coactivator 1 (PGC1) invigorated by AMPK. In line with this, it was detailed that, in non - diabetic subjects, the administration of

metformin for 2 months might increase the incline mass and water content [63]. Together, these discoveries, in spite of the irregularities in the effects on body composition, highlight the need to consider the effects of skeletal mass and execution when planning metformin - based treatment for diabetes. Considering the reality that metformin may actuate craving concealment and restraint of intestinal oligopeptide absorption, [64] the chance of sarcopenia with clinical metformin treatment ought to be born in intellect, particularly in ladies with T2DM and senior patients.

4.4 Thiazolidinediones

Thiazolidinediones (TZDs), ordinarily counting rosiglitazone and pioglitazone, are regularly endorsed for diabetic patients to upgrade affectability within the muscle, liver, and fat tissue through the enactment of peroxisome proliferator - activated receptor gamma (PPAR -). TZDs, as affront sensitising operators, may play a dynamic part in keeping up SMM and work, as appeared by preclinical ponders. In specific, studies with skeletal muscle cells revealed that rosiglitazone decreased apoptosis through a PPAR - dependent mechanism [65]. It was too detailed to say that rosiglitazone strongly restrains fiery mediator - induced atomic factor - kappa B (NF - B) translation, which may weaken protein corruption in refined skeletal muscle myotubes [66]. This viewpoint incorporates clinical thinking and information. An early multicentre longitudinal study by Lee et al. detailed that TZD may diminish the misfortune of muscle mass in patients with impeded fasting glucose or diabetes [63]. Be that as it may, the ACT Presently, it appears that the lean body mass within the legs was altogether lower after 33.6 months of pioglitazone treatment in subjects with prediabetes, with a critical increment in body weight and no alteration in by and large incline body mass [67]. Undoubtedly, prior case reports showed intense rhabdomyolysis in T2DM patients after pioglitazone or troglitazone treatment. [68, 69] Subsequently, caution is required when endorsing TZDs to understand skeletal muscle issues. Various studies have indicated that TZDs decrease muscle lipid substance by lessening greasy corrosive (FA) take - up, lifting FA oxidation, and expanding FA transport capacity from muscle into subcutaneous fat tissue [70]. A randomised cross - over study found that, in spite of the fact that there was no alteration in body weight or fat after Pioglitazone was utilised in non - diabetic patients for 4 months, and the visceral/subcutaneous fat tissue proportion was diminished by 16% [71]. This was adjusted with another finding that pioglitazone essentially improved the whole - body high - impact capacity and skeletal muscle FA digestion systems in patients with metabolic syndrome [72]. As intermuscular and intramyocellular lipid overburden may cause affront resistance, skeletal muscle squandering, and dysfunction, [73]. the lipid - lowering impact of TZDs is hypothetically valuable to reinforce muscle substance and work. More well - designed clinical trials are hence required to clarify the impacts of TZDs on sarcopenia in T2DM patients.

4.5 Glucagon - like peptide - 1 analogues

Glucagon - like peptide - 1 (GLP - 1) is a naturally occurring incretin hormone secreted from intestinal L - cells and exerts a number of potentially anti - hyperglycemic actions, including enhancement of glucose - dependent insulin secretion, restoration of the glucose sensitivity of pancreatic L - cells, and suppression of glucagon release [74]. GLP - 1 analogues, such as exenatide and liraglutide, produce many of the glucoregulatory actions observed with endogenous GLP - 1. Several studies have reported that GLP - 1 or GLP - 1 analogues can cause weight loss in animals and humans [75, 76]. The mechanisms are likely attributed to decreased energy intake (e. g., delayed gastric emptying, gastric secretion, and motility), appetite sensation, increased energy expenditure, and perception of satiety. Weight loss induced by GLP - 1 analogue treatment primarily comes from reductions in FM rather than lean mass, as already demonstrated in some observational studies [77 - 80]. Specifically, it was shown that the relative total body FM was reduced by 2.3% while the relative total body lean mass was increased by 2.3% following a 12 - week liraglutide treatment in obese T2DM patients with metformin [81]. Similar results were found in another study [82]. Interestingly, Li and colleagues also found significant correlations between weight loss and increases in both plasma atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) levels, suggesting that liraglutide - induced changes in body composition might be associated with changes in the NP system.

By studying the effect of hypoxia on sarcopenia, it was found that GLP - 1 is the strongest predictor of FFM loss, suggesting that GLP - 1 analogues (such as exendin - 4) can be used to reduce sarcopenia risks [83]. Perna et al. evaluated liraglutide in overweight and obese elderly patients with T2DM. After 24 weeks of treatment, it was found that the reduction in body weight was mainly due to the decrease in FM, and liraglutide could prevent the degradation of muscle protein and maintain the stability of skeletal muscle [84]. However, in another study involving 21 T2DM patients undergoing hemolysis, the addition of dulaglutide to insulin therapy significantly decreased FM and SMM, suggesting the sarcopenia risk of this drug [85]. A recent meta - analysis of randomised controlled trials also indicated that semaglutide was associated with both weight loss and FFM decreases, prompting the need to understand drug - specific effects on sarcopenic parameters [86].

4.6 Dipeptidyl peptidase IV inhibitors:

Dipeptidyl peptidase IV (DPP - IV) inhibitors such as sitagliptin, vildagliptin, and saxagliptin increment endogenous GLP - 1 to achieve a glucose - lowering impact. Whereas DPP - IV inhibitors do not increment the weight of T2DM patients, thinks about having found that it has the potential to cause strides in skeletal muscle damage. As mentioned prior, development clutters individuals with Diabetes basically happens within the lower appendage, particularly in the quadriceps femoris. In a review, consider Bouchi et al. confirmed the defensive impact of DPP - IV inhibitors on muscledys function in T2DM patients, particularly on the lower limb muscle, demonstrating a guarantee of DPP - IV inhibitors in clinical intervention for muscle loss [87]. In a clinical study of 80 elderly patients with T2DM, treatment with DPP - IV inhibitors (Vildagliptin 50 mg offered, sitagliptin 100 mg/day, or

saxagliptin5 mg/day) appeared to have way better sarcopenic parameters (FFM, SMM, muscle quality, and walk speed) compared with sulfonylurea treatment [88]. These clinical benefits are bolstered by studies from creatures. For illustration, Bianchi et al. appeared to argue thatPKF275 - 055 (a vildagliptin simple) might, in part, improve the harm to white fibre muscle initiated by streptozotocinin sort 1 diabetic rats [89]. Enoki et al. found that teneligliptin had the potential to treat muscle breakage in persistent renal disease (CKD) mice, and it was recommended that teneligliptin could not, as it were, by implication, play a cellular defensive role. Through GLP - 1 but too specifically act on muscle decay induced by CKD [90]. In expansion, Giannocco et al. found that Sitagliptin may up - regulate the uprooting and expression of GLUT4 in the myocardium and skeletal muscle of spontaneously hypertensive rats [91]. Interestingly, the FDA has cautioned that high - dose DPP – IV Inhibitors can initiate intense poisonous qualities in monkeys, including the increment in creatine kinase (CK) action, the pathological elevation, which is commonly watched with muscular dystrophy. In specific, a tall dosage (160 mg/kg) of vildagliptin was utilised within the tests with the Cynomolgus monkey [92]. It was found that a few creatures had very high CK activity. (more than 40 000 U/L), and anatomical discoveries of skeletal muscle rot and intramuscular dying in the extremities. However, the analysts also recommend that the intense toxicity caused by vildagliptin shows up to be one of a kind in monkeys, and it is dubious whether it will happen to humans. Therefore, more investigation is required to determine the impacts of DPP - IVinhibitors on skeletal muscle in clinical use. A later study found that in metformin - treated T2DM, A protein preload has the capacity to upgrade the viability of vildagliptin to moderate gastric purging, increment plasma intactincretins and diminish postprandial glycaemia, demonstrating that Vildagliptin has the potential to decrease the chance of weight gain. in patients with T2DM [93]. Be that as it may, Run et al. proposed that Vildagliptin may increase lipid capacity in fat tissue and reduce fat in muscle and liver, [92], and a huge number of Studies have shown that DPP - IV inhibitors have no significant effect on the body weight of a human or rodent [94, 95]. FutureStudies are hence justified to efficiently evaluatethe impact of DPP - IV inhibitors on body composition, especiallythe fat and inclined mass.

4.7 Sodium - glucose co - transporter 2 inhibitors:

Sodium - glucose co - transporter 2 (SGLT2) inhibitors selectively restrain SGLT2 to diminish proximal tubular glucose reabsorption, hence expanding urinary sugar excretion to reduce blood glucose concentration. As of now, the representative drugs utilised include dapagliflozin, canagliflozin, empagliflozin, ipragliflozin, tofogliflozin, and luseogliflozin [96]. SGLT2 inhibitors have a well - confirmed impact on initiating weight misfortune, and about 90% of weight misfortune is due to a decrease in FM [97 - 99]. Other considerations have also revealed that the use of SGLT2 is beneficial. Inhibitors in T2DM patients diminish FM by two - thirds and lean mass by one - third [100, 101]. Ordinarily, both ipragliflozin and Canagliflozin decreases the weight of FM and incline mass [102, 103]. However, a randomised controlled trial found thatDapagliflozin essentially diminished subcutaneous and visceral abdominal fat after 24 weeks of treatment but had no effect. On incline tissue [104]. Sasaki et al. found that SMM in T2DM patients treated with luseogliflozin did not alter significantly. Until 36 weeks after treatment, whereas bone mineral content (BMC) diminished, as it were, briefly after 12 weeks, and then remained unchanged [105]. In line with these clinical discoveries, when diet - induced when obese (DIO) rats were treated with tofogliflozin, there wasno noteworthy alteration in bone mass or incline mass [106]. Naznin et al. found that treatment with canagliflozin for8 weeks may initiate body weight misfortune in mice, characterised by diminished masses of visceral and subcutaneous fat [107]. Despite these discoveries, there are still concerns that SGLT2Inhibitors may lead to muscle and bone mass misfortune, osteoporosis, and diminished body function [108]. In this manner, in spite of the fact that most of current thoughts about SGLT2 inhibitors having no antagonistic impacts on skeletal muscle, [109 - 113] more considerations are needed to investigate the impacts of SGLT2 inhibitors on muscle.

5. Pharmacological Treatment

Different drugs have been endorsed for the treatment of diabetes mellitus. In differentiate, small prove is as of now accessible for the pharmacological treatment of slightness. As depicted above, there are numerous mediations for the clinical administration of slightness, such as physical exercise, a solid slim down, or complication avoidance programmes. The deprescription of superfluous solutions can also be useful. Be that as it may, we don't have logical proof with respect to the utilisation of particular drugs against feebleness [114]. Additionally, sarcopenia does not have particular pharmacological medications, and its administration is based on advancing physical movement, a sound diet, and maintaining a strategic distance from related complications [115]. Be that as it may, a few antidiabetic operators might have vital roles in muscle physiology [116]. Underneath, the most common antidiabetic drugs and their association with sarcopenia and/or feebleness in the elderly are checked.

5.1 Biguanides:

Metformin could be a medication broadly utilised in the administration of T2DM. Multiple studies bolster its use. Hence, metformin is the first - line treatment for the endless lion's share of cases of T2DM. In elderly patients, metformin has not been considered in particular clinical trials, but it is commonly utilised due to the broad clinical encounter [117]. Metformin does not more often than not cause hypoglycemia, and it is valuable in patients with cardiovascular illness or steady heart failure. Be that as it may, within the elderly, burdens such as stomach - related narrow - mindedness, dysgeusia, hyporexia, and vitamin B12 deficiency may show up [118]. In expansion, its utilisation must be balanced with renal function. With respect to sarcopenia, in spite of the fact that the exact instruments are not clearly recognised, diverse theories appear to indicate that metformin clearly has positive impacts on both muscle mass and muscle quality [116, 119]. For illustration, Aghili et al. proposed that recently analysed T2DM patients treated with metformin 1000 mg twice every

day had a noteworthy increment in skeletal mass [120]. Other studies suggested that metformin presentation was related to a lower chance of feebleness after adjustment for covariates [121]. In any case, clinical trials are essential to getting more steady results [122].

5.2 Sulfonylureas Sulfonylureas:

Have been broadly utilized drugs due to their moo fetched and the diminish in microvascular complications of T2DM [123]. They are ATP - sensitive potassium channel blockers. The discharge of affront from the β cells of the pancreas is fortified by these antidiabetic pills. They are as of now neglected drugs, particularly within the elderly, due to the chance of hypoglycemia, the weight pick up they create, or the numerous pharmacological intuitive they show (fibrates, allopurinol, salicylates, dicumarinics, methotrexate, beta - blockers, corticosteroids).

We have restricted prove in “in vivo” considers. In “in vitro” ponders, it is watched that sulfonylureas favor muscle decay, hence they ought to be dodged in patients with sarcopenia or at hazard of creating sarcopenia [124, 125]. Based on creature tests, the slightest successful sulfonylurea as an atrophic operator was glimepiride [125]. On the other hand, assessment of slightness ought to be performed intermittently in more seasoned patients taking sulfonylureas due to the chance of displaying complications since of the antagonistic impacts of these antidiabetics [126, 127].

5.3 Meglintinides

Glinides have a comparable component of activity to sulfonylureas. A few contrasts compared to sulfonylureas are their shorter circulating half - life, fast assimilation, end through the liver, and their activity basically on postprandial glucose levels. Just like the sulfonylureas, these specialists have a high chance of hypoglycemia, and thus they are not prescribed to the elderly [128, 129]. Moreover, these drugs must be utilised with dinner, so their use isn't suggested in patients with destitute eating propensities [129]. Inside the glinides, few ponders have been distributed in sarcopenia, in spite of the fact that their solid atrophic impact is known. Repaglinide is the foremost strong in vitro atrophic operator in creatures [124], whereas other studies have shown that glibenclamide actuates decay in creature tests and in human patients [125].

5.4 Thiazolidinediones

Thiazolidinediones ought not be the first choice of drugs in elderly patients due to the comorbidities that these patients ordinarily show. A few of their best - known unfavourable impacts are decompensated heart disappointment and the chance of breaks. Visit this quiet profile. This circumstance limits its use in more experienced diabetic patients [130]. In contrast, thiazolidinediones don't create lactic acidosis or hypoglycemia. Pioglitazone is still in use; in any case, rosiglitazone was suspended by the European Solutions Organisation due to its side effects [131]. Being insulin sensitizers, a few consider the advantageous impacts of thiazolidinediones on muscle execution in diabetic patients. Pioglitazone makes strides towards vitality in skeletal muscle by diminishing intramyocellular lipid substances and moving forward the greasy, corrosive digestion system [132]. In outline, these drugs are promising anti - atrophy specialists, but the unfavourable benefit - risk profile related to cardiovascular and antagonistic events limits their utilisation within the elderly [133].

5.5 Incretins

Dipeptidyl peptidase - 4 (DDP - 4) inhibitors and glucagon - like peptide - 1 (GLP - 1) agonists are drugs that have recently joined the helpful arms stockpile of T2DM. DPP - 4 inhibitors have few side effects and a negligible risk of hypoglycemia [134]. They can be utilised securely, without chance of hypoglycemia, at any stage of unremitting renal disappointment. All of them require dosage alteration in cases of direct or serious renal lack, except linagliptin, which experiences a biliary end. They don't alter body weight or show noteworthy sedate interactions [135]. They don't cause stomach - related narrow - mindedness either. These are all critical points of interest for elderly patients. DDP - 4 inhibitors may increase muscle mass, although their mechanism is vague. It might be related to capacity to improve GLP - 1 activity, hindrance of DPP - 4 activity per se, or both [119]. GLP - 1 agonists have illustrated anti - oxidative and anti - inflammatory properties, in conjunction with anti - thrombotic impacts, that might be supportive in feebleness patients due to the high burden of cardiovascular comorbidities that these patients as a rule show [136, 137]. Be that as it may, although the components with respect to the impacts of GLP - 1 agonists on skeletal muscle proceed as a matter of wrangling about, the weight misfortune and diminished craving delivered by GLP - 1 agonists may have undesirable impacts within the elderly, in whom hyporexia and ailing health are common. Weight misfortune at the cost of incline mass can be counterproductive in patients with sarcopenia. They may also be related to queasiness, heaviness, and loose bowels [138]. In this manner, GLP - 1 agonists can be utilised with caution in the elderly, but they ought not be managed in the slight elderly.

5.6 Sodium - Glucose Cotransporter 2 (SGLT - 2) Inhibitors:

Its component of activity is to anticipate glucose reabsorption within the renal tubule and actuate glycosuria. This family of drugs has shown benefits in patients with heart disappointment, cardiovascular benefits in patients with built - up cardiovascular infection, and postponed movement of unremitting kidney infection, more often than not in elderly and diabetic patients [139–141]. SGLT2 inhibitors have demonstrated themselves to be a great restorative alternative for the treatment of DM2 in more seasoned patients. They have a low hazard of hypoglycemia, diminish blood weight, and provide cardiovascular and renal safety and protection. However, these drugs ought to be introduced with caution to the elderly who are taking other medicines such as affront or hypotensive drugs [142]. It is vital to avoid excessive volume consumption due to osmotic diuresis in adult patients [143]. In expansion, due to its hypotensive impact, the presence of orthostatic hypotension in elderly diabetic patients must be surveyed [144]. Another complication that we must assess is the presence of genital mycoses or urinary contaminations that can complicate the

advancement of mild patients. There is currently no logical evidence accessible on the impacts of these drugs on muscle. Future studies are required to consider whether SGLT2 inhibitors have atrophic or antiatrophic impacts [145].

5.7 Insulin

Insulin is the most effective hypoglycemic drug ever known. Adults with diabetes who take insulin therapy are at risk for diabetes, falls, and fractures. Therefore, the use of insulin in adults should be individual. For adults, oral therapy is preferred to insulin. Basal insulin analogues are preferred to human insulin as they generally have a lower risk of hypoglycemia at night, despite their high cost. If insulin is required, it is best to use simple instructions and avoid radical glycemic control [146, 147]. Insulin stimulates muscle protein synthesis in young subjects but not in the elderly. Insulin therapy does not prevent skeletal muscle atrophy, probably because insulin resistance develops with age [148, 149]. There is no evidence that insulin therapy is effective for sarcopenia in the elderly.

6. Conclusions

T2DM, sarcopenia, and slightness are commonly related and frequently coexist. Their nearness may be a marker of destituteness in elderly patients. It is recommended to avoid over - the - top glycemic control, with the objective of maintaining a strategic distance from hypoglycemia and symptomatic hyperglycemias. Screening and early detection of sarcopenia and/or feebleness are prescribed utilising programmes aimed at improving the outlook and quality of life of patients. Likely, the need for accessible information on modern, continuous considerations that have not yet been distributed may be a limitation. Advance considerations on the joint administration of these three pathologies are suggested due to their expanding predominance and the rareness of their distribution to date.

References

[1] Lee CG, Boyko EJ, Strotmeyer ES, et al. Association between insulin resistance and lean mass loss and fat mass gain in older men without diabetes mellitus. J Am Geriatr Soc.2011; 59 (7): 1217–1224. doi: 10.1111/j.1532 - 5415.2011.03472. x

[2] Cruz - Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010; 39: 412–423.

[3] Bezerra, C. B.; Pinho, C. B. R. P.; Saintrain, M. V. L.; Sodré, A. K. M. B.; Silva, C. A. B. D.; Doucet, J. Characteristics of the clinical treatment of Brazilian and French older adults with diabetes. Diabetes Res. Clin. Pract.2021, 181, 109088.

[4] Gómez - Huelgas, R.; Peralta, F. G.; Mañas, L. R.; Formiga, F.; Domingo, M. P.; Bravo, J. M.; Miranda, C.; Ena, J. Tratamiento de la diabetes mellitus tipo 2 enelpacienteanciano Treatment of type 2 diabetes mellitus in elderly patients. Rev. Esp. Geriatr. Gerontol.2018, 53, 89–99. (In Spanish)

[5] Mcternan PG, Kusminski CM, Kumar S. Recent advances in the relationship between obesity, inflammation, insulin resistance. Eur Cytokine Netw. (2006) 17: 4–12. doi: 10.1104/pp.92.4.891

[6] Shoelson SE, Herrero L, Naaz Obesity A. Inflammation, insulin resistance. Gastroenterology. (2007) 132: 2169–80. doi: 10.1053/j. gastro.2007.03.059

[7] Matulewicz N, Karczewska - Kupczewska M. Insulin resistance and chronic inflammation. PostepyHig Med Dosw. (2016) 70: 1245–58. doi: 10.5604/17322693.1226662

[8] Nomura T, Ikeda Y, Nakao S, Ito K, Ishida K, Suehiro T, et al. Muscle strength is a marker of insulin resistance in patients with type 2 diabetes: a pilot study. Endocr J. (2007) 54: 791–6. doi: 10.1507/endocrj. K07 - 055

[9] Abbatecola AM, Ferrucci L, Ceda G, Russo CR, Lauretani F, Bandinelli S, et al. Insulin resistance and muscle strength in older persons. J Gerontol. (2005) 60: 1278–82. doi: 10.1093/gerona/60.10.1278

[10] Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al. PGC - 1α - responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. (2003) 34: 267– 73. doi: 10.1038/ng1180

[11] Patti ME, Butte AJ, Crunkhorn S, Cusi K, Mandarino LJ. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci USA. (2003) 100: 8466–71. doi: 10.1073/pnas.1032913100

[12] Abbatecola AM, Paolisso G, Fattoretti P, Evans WJ, Fiore V, Dicioccio L, et al. Discovering pathways of sarcopenia in older adults: a role for insulin resistance on mitochondria dysfunction. J Nutr Health Aging. (2011) 15: 890– 5. doi: 10.1007/s12603 - 011 - 0366 - 0

[13] Huh JY. The role of exercise - induced myokines in regulating metabolism. Arch Pharm Res. (2018) 41: 14–29. doi: 10.1007/s12272 - 017 - 0994 - y

[14] Díaz BB, González DA, Gannar F, Pérez MCR, de León AC. Myokines, physical activity, insulin resistance and autoimmune diseases. Immunol Lett. (2018) 203: 1–5. doi: 10.1016/j. imlet.2018.09.002

[15] Chang JS, Kim TH, Nguyen TT, Park K - S, Kim N, Kong ID. Circulating irisin levels as a predictive biomarker for sarcopenia: a cross - sectional communitybased study. GeriatrGerontol Int. (2017) 17: 2266–73. doi: 10.1111/ ggi.13030

[16] Colaianni G, Cinti S, Colucci S, Grano M. Irisin and musculoskeletal health. Ann N Y Acad Sci. (2017) 1402: 5–9. doi: 10.1111/nyas.13345

[17] Wang C, Bai L. Sarcopenia in the elderly: basic and clinical issues. GeriatrGerontol Int. (2012) 12: 388–96 doi: 10.1111/j.1447 - 0594.2012.00851. x

[18] Choi KM. Sarcopenia and sarcopenic obesity. Endocrinol Metab (Seoul). (2013) 28: 86–9 doi: 10.3803/EnM.2013.28.2.86

[19] Weltman A, Weltman J, Veldhuis JD, Hartman ML. Body composition, physical exercise, growth

hormone and obesity. Eat Weight Disord. (2001) 6 (3 Suppl): 28–37.
[20] Waters DL, Qualls CR, Dorin RI, Veldhuis JD, Baumgartner RN. Altered growth hormone, cortisol, and leptin secretion in healthy elderly persons with sarcopenia and mixed body composition phenotypes. J Gerontol. (2008) 63: 536–41. doi: 10.1093/gerona/63.5.536
[21] Sipilä S, Narici M, Kjaer M, Pöllänen E, Atkinson RA, Hansen M, et al. Sex hormones and skeletal muscle weakness. Biogerontology. (2013) 14: 231–45. doi: 10.1007/s10522 - 013 - 9425 - 8
[22] Hoogendijk, E. O.; Afilalo, J.; Ensrud, K. E.; Kowal, P.; Onder, G.; Fried, L. P. Frailty: Implications for clinical practice and public health. Lancet 2019, 394, 1365–1375.
[23] Sinclair, A. J.; Rodriguez - Mañas, L. Diabetes and Frailty: Two Converging Conditions? Can. J. Diabetes 2016, 40, 77–83.
[24] Rolland, Y.; Czerwinski, S.; Abellan Van Kan, G.; Morley, J. E.; Cesari, M.; Onder, G.; Woo, J.; Baumgartner, R.; Pillard, F.; Boirie, Y.; et al. Sarcopenia: Its assessment, etiology, pathogenesis, consequences and future perspectives. J. Nutr. Health Aging 2008, 12, 433–450.
[25] Serra - Prat, M.; Palomera, E.; Clave, P.; Puig - Domingo, M. Effect of age and frailty on ghrelin and cholecystokinin responses to a meal test. Am. J. Clin. Nutr.2009, 89, 1410–1417.
[26] Fried, L. P.; Tangen, C. M.; Newman, A. B.; Hirsch, C.; Gottdiener, J.; Seeman, T.; Tracy, R.; Kop, W. J.; Burke, G.; McBurnie, M. A. Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: Evidence for a phenotype. J. Gerontol. A Biol. Sci. Med. Sci.2001, 56, 146–156.
[27] Nishikawa, H.; Fukunishi, S.; Asai, A.; Yokohama, K.; Ohama, H.; Nishiguchi, S.; Higuchi, K. Sarcopenia, frailty and type 2 diabetes mellitus (Review). Mol. Med. Rep.2021, 24, 854.
[28] Tamura, Y.; Omura, T.; Toyoshima, K.; Araki, A. Nutrition Management in Older Adults with Diabetes: A Review on the Importance of Shifting Prevention Strategies from Metabolic Syndrome to Frailty. Nutrients 2020, 12, 3367.
[29] Assar, M. E.; Laosa, O.; Mañas, L. R. Diabetes and frailty. Curr. Opin. Clin. Nutr. Metab. Care 2019, 22, 52–57.
[30] Umegaki, H. Sarcopenia and frailty in older patients with diabetes mellitus. Geriatr. Gerontol. Int.2016, 16, 293–299.
[31] Ida, S.; Kaneko, R.; Imataka, K.; Murata, K. Relationship between frailty and mortality, hospitalization, and cardiovascular diseases in diabetes: A systematic review and meta - analysis. Cardiovasc. Diabetol.2019, 18, 81.
[32] Khalifa, M. Improving Patient Safety by Reducing Falls in Hospitals among the Elderly: A Review of Successful Strategies. ICIMTH 2019, 262, 340–343. Int. J. Environ. Res. Public Health 2022, 19, 8677 11 of 13
[33] Massimino, E.; Izzo, A.; Riccardi, G.; Della Pepa, G. The Impact of Glucose - Lowering Drugs on Sarcopenia in Type 2 Diabetes: Current Evidence and Underlying Mechanisms. Cells 2021, 10, 1958.
[34] Cruz - Jentoft, A. J.; Bahat, G.; Bauer, J.; Boirie, Y.; Bruyère, O.; Cederholm, T.; Cooper, C.; Landi, F.; Rolland, Y.; Sayer, A. A.; et al. Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: Revised European consensus on definition and diagnosis. Age Ageing 2019, 48, 16–31.
[35] Cruz - Jentoft, A. J.; Sayer, A. A. Sarcopenia. Lancet 2019, 393, 2636–2646.
[36] Izzo, A.; Massimino, E.; Riccardi, G.; Della Pepa, G. A Narrative Review on Sarcopenia in Type 2 Diabetes Mellitus: Prevalence and Associated Factors. Nutrients 2021, 13, 183.
[37] Papadopoulou, S. Sarcopenia: A Contemporary Health Problem among Older Adult Populations. Nutrients 2020, 12, 1293.
[38] Sinclair, A.; Dunning, T.; Rodriguez - Mañas, L. Diabetes in older people: New insights and remaining challenges. Lancet Diabetes Endocrinol.2015, 3, 275–285.
[39] Weiskopf, D.; Weinberger, B.; Grubeck - Loebenstein, B. The aging of the immune system. Transpl. Int.2009, 22, 1041–1050.
[40] Wilson, D.; Jackson, T.; Sapey, E.; Lord, J. M. Frailty and sarcopenia: The potential role of an aged immune system. Ageing Res. Rev.2017, 36, 1–10.
[41] Barbé - Tuana, F.; Funchal, G.; Schmitz, C. R. R.; Maurmann, R.; Bauer, M. E. The interplay between immunosenescence and age - related diseases. Semin. Immunopathol.2020, 42, 545–557.
[42] Wang, M.; Tan, Y.; Shi, Y.; Wang, X.; Liao, Z.; Wei, P. Diabetes and Sarcopenic Obesity: Pathogenesis, Diagnosis, and Treatments. Front. Endocrinol.2020, 11, 568.
[43] Nauck MA, Wefers J, Meier JJ. Treatment of type 2 diabetes: challenges, hopes, and anticipated successes. Lancet Diabetes Endocrinol 2021; 9: 525–544.
[44] Zheng C, Liu Z. Vascular function, insulin action, and exercise: an intricate interplay. Trends Endocrinol Metab 2015; 26: 297–304.
[45] Tanaka K, Kanazawa I, Sugimoto T. Reduction in endogenous insulin secretion is a risk factor of sarcopenia in men with type 2 diabetes mellitus. Calcif Tissue Int 2015; 97: 385–390.
[46] Bouchi R, Fukuda T, Takeuchi T, Nakano Y, Murakami M, Minami I, et al. Insulin treatment attenuates decline of muscle mass in Japanese patients with type 2 diabetes. Calcif Tissue Int 2017; 101: 1–8.
[47] Ferrari U, Then C, Rottenkolber M, Selte C, Seissler J, Conzade R, et al. Longitudinal association of type 2 diabetes and insulin therapy with muscle parameters in the KORA - Age study. Acta Diabetol 2020; 57: 1057–1063.
[48] Salle A, Guilloteau G, Ryan M, Bouhanick B, Ritz P. Effect of insulin treatment on the body composition of Type 2 diabetic patients. Diabet Med 2004; 21: 1298–1303.
[49] Sinha A, Formica C, Tsalamandris C, Panagiotopoulos S, Hendrich E, DeLuise M, et al.

Effects of insulin on body composition in patients with insulin - dependent and non - insulin - dependent diabetes. Diabet Med 1996; 13: 40–46.
[50] Birkeland KI, Hanssen KF, Urdal P, Berg K, Vaaler S. A long - term, randomized, comparative study of insulin versus sulfonylurea therapy in type 2 diabetes. J Intern Med 1994; 236: 305–313.
[51] Zhang H, Hanson A, de Almeida TS, Emfinger C, McClenaghan C, Harter T, et al. Complex consequences of Cantu syndrome SUR2 variant R1154Q in genetically modified mice. JCI Insight 2021; 6: e145934.
[52] Tricarico D, Mele A, Lundquist AL, Desai RR, George AL Jr, Conte Camerino D. Hybrid assemblies of ATP - sensitive K+ channels determine their muscle - type - dependent biophysical and pharmacological properties. Proc Natl Acad Sci U S A 2006; 103: 1118–1123.
[53] Tricarico D, Mele A, Camerino GM, Bottinelli R, Brocca L, Frigeri A, et al. The KATP channel is a molecular sensor of atrophy in skeletal muscle. J Physiol2010; 588: 773–784.
[54] Mele A, Buttiglione M, Cannone G, Vitiello F, Camerino DC, Tricarico D. Opening/ blocking actions of pyruvate kinase antibodies on neuronal and muscular KATP channels. Pharmacol Res 2012; 66: 401–408.
[55] Mele A, Calzolaro S, Cannone G, Cetrone M, Conte D, Tricarico D. Database search of spontaneous reports and pharmacological investigations on the sulfonylureas and glinides - induced atrophy in skeletal muscle. Pharmacol Res Perspect 2014; 2: e00028.
[56] Ishii S, Nagai Y, Kato H, Fukuda H, Tanaka Y. Effect of the dipeptidyl peptidase - 4 inhibitor sitagliptin on muscle mass and the muscle/fat ratio in patients with type 2 diabetes. J Clin Med Res 2020; 12: 122–126
[57] Vancura A, Bu P, Bhagwat M, Zeng J, Vancurova I. Metformin as an anticancer agent. Trends Pharmacol Sci 2018; 39: 867–878.
[58] Foretz M, Guigas B, Viollet B. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nat Rev Endocrinol 2019; 15: 569–589.
[59] Aghili R, Malek M, Valojerdi AE, Banazadeh Z, Najafi L, Khamseh ME. Body composition in adults with newly diagnosed type 2 diabetes: effects of metformin. J Diabetes MetabDisord2014; 13: 88.
[60] Rodriguez - Moctezuma JR, Robles - Lopez G, Lopez - Carmona JM, Gutierrez - Rosas MJ. Effects of metformin on the body composition in subjects with risk factors for type 2 diabetes. Diabetes ObesMetab2005; 7: 189–192.
[61] Wang H, Ni Y, Yang S, Li H, Li X, Feng B. The effects of gliclazide, metformin, and acarbose on body composition in patients with newly diagnosed type 2 diabetes mellitus. CurrTher Res Clin Exp 2013; 75: 88–92.
[62] Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P, Rooyackers O, et al. Metformin increases AMP - activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002; 51: 2074–2081.
[63] Lee CG, Boyko EJ, Barrett - Connor E, Miljkovic I, Hoffman AR, Everson - Rose SA, et al. Insulin sensitizers may attenuate lean mass loss in older men with diabetes. Diabetes Care 2011; 34: 2381–2386.
[64] Hindlet P, Barraud C, Boschat L, Farinotti R, Bado A, Buyse M. Rosiglitazone and metformin have opposite effects on intestinal absorption of oligopeptides via the proton - dependent PepT1 transporter. Mol Pharmacol2012; 81: 319–327.
[65] Meshkani R, Sadeghi A, Taheripak G, Zarghooni M, Gerayesh - Nejad S, Bakhtiyari S. Rosiglitazone, a PPARγ agonist, ameliorates palmitate - induced insulin resistance and apoptosis in skeletal muscle cells. Cell BiochemFunct2014; 32: 683–691.
[66] Remels AH, Langen RC, Gosker HR, Russell AP, Spaapen F, Voncken JW, et al. PPARγ inhibits NF - κB - dependent transcriptional activation in skeletal muscle. Am J Physiol Endocrinol Metab 2009; 297: E174–E183.
[67] Bray GA, Smith SR, Banerji MA, Tripathy D, Clement SC, Buchanan TA, et al. Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial. Diabetes ObesMetab2013; 15: 931–937.
[68] Slim R, Ben Salem C, Zamy M, Biour M. Pioglitazone - induced acute rhabdomyolysis. Diabetes Care 2009; 32: e84.
[69] Yokoyama M, Izumiya Y, Yoshizawa M, Usuda R. Acute rhabdomyolysis associated with troglitazone. Diabetes Care 2000; 23: 421–422.
[70] Hu S, Yao J, Howe AA, Menke BM, Sivitz WI, Spector AA, et al. Peroxisome proliferator - activated receptor gamma decouples fatty acid uptake from lipid inhibition of insulin signaling in skeletal muscle. Mol Endocrinol 2012; 26: 977–988.
[71] Zanchi A, Tappy L, Le KA, Bortolotti M, Theumann N, Halabi G, et al. Pioglitazone improves fat distribution, the adipokine profile and hepatic insulin sensitivity in non - diabetic end - stage renal disease subjects on maintenance dialysis: a randomized cross - over pilot study. PLoS ONE 2014; 9: e109134.
[72] Yokota T, Kinugawa S, Hirabayashi K, Suga T, Takada S, Omokawa M, et al. Pioglitazone improves whole - body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome. J Diabetes Investig 2017; 8: 535–541.
[73] Tamilarasan KP, Temmel H, Das SK, Al Zoughbi W, Schauer S, Vesely PW, et al. Skeletal muscle damage and impaired regeneration due to LPL - mediated lipotoxicity. Cell Death Dis 2012; 3: e354.
[74] Gribble FM, Reimann F. Function and mechanisms of enteroendocrine cells and gut hormones in metabolism. Nat Rev Endocrinol 2019; 15: 226–237.
[75] Wang G, Wu P, Qiu Y, Dong X, Wang Y, Chi Y, et al. Effect of beinaglutide treatment on weight loss in Chinese patients with type 2 diabetes mellitus and overweight/ obesity. Arch Endocrinol Metab 2021.
[76] Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH. SGLT2 inhibitors and GLP - 1 receptor agonists: established and emerging indications. Lancet 2021; 398: 262–276.
[77] Bradley DP, Kulstad R, Racine N, Shenker Y, Meredith M, Schoeller DA. Alterations in energy

balance following exenatide administration. ApplPhysiolNutrMetab2012; 37: 893–899.
[78] Seko Y, Sumida Y, Tanaka S, Mori K, Taketani H, Ishiba H, et al. Effect of 12 - week dulaglutide therapy in Japanese patients with biopsy - proven non - alcoholic fatty liver disease and type 2 diabetes mellitus. Hepatol Res 2017; 47: 1206–1211.
[79] Rondanelli M, Perna S, Astrone P, Grugnetti A, Solerte SB, Guido D. Twenty - four - week effects of liraglutide on body composition, adherence to appetite, and lipid profile in overweight and obese patients with type 2 diabetes mellitus. Patient Prefer Adherence 2016; 10: 407–413.
[80] Hong JY, Park KY, Kim BJ, Hwang WM, Kim DH, Lim DM. Effects of short - term exenatide treatment on regional fat distribution, glycated hemoglobin levels, and aortic pulse wave velocity of obese type 2 diabetes mellitus patients. Endocrinol Metab (Seoul) 2016; 31: 80–85.
[81] Li CJ, Yu Q, Yu P, Yu TL, Zhang QM, Lu S, et al. Changes in liraglutide - induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients. Cardiovasc Diabetol2014; 13: 36.
[82] Diaz - Soto G, de Luis DA, Conde - Vicente R, Izaola - Jauregui O, Ramos C, Romero E. Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study. Diabetes Res Clin Pract2014; 104: 92–96.
[83] Wandrag L, Siervo M, Riley HL, Khosravi M, Fernandez BO, Leckstrom CA, et al. Does hypoxia play a role in the development of sarcopenia in humans? Mechanistic insights from the Caudwell Xtreme Everest Expedition. Redox Biol2017; 13: 60–68.
[84] Perna S, Guido D, Bologna C, Solerte SB, Guerriero F, Isu A, et al. Liraglutide and obesity in elderly: efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study. Aging Clin Exp Res 2016; 28: 1251–1257.
[85] Yajima T, Yajima K, Takahashi H, Yasuda K. The effect of dulaglutide on body composition in type 2 diabetes mellitus patients on hemodialysis. J Diabetes Complications 2018; 32: 759–763.
[86] Ida S, Kaneko R, Imataka K, Okubo K, Shirakura Y, Azuma K, et al. Effects of antidiabetic drugs on muscle mass in type 2 diabetes mellitus. Curr Diabetes Rev 2021; 17: 293–303.
[87] Bouchi R, Fukuda T, Takeuchi T, Nakano Y, Murakami M, Minami I, et al. Dipeptidyl peptidase 4 inhibitors attenuates the decline of skeletal muscle mass in patients with type 2 diabetes. Diabetes Metab Res Rev 2018; 34.
[88] Rizzo MR, Barbieri M, Fava I, Desiderio M, Coppola C, Marfella R, et al. Sarcopenia in elderly diabetic patients: role of dipeptidyl peptidase 4 inhibitors. J Am Med Dir Assoc 2016; 17: 896–901.
[89] Bianchi R, Cervellini I, Porretta - Serapiglia C, Oggioni N, Burkey B, Ghezzi P, et al. Beneficial effects of PKF275 - 055, a novel, selective, orally bioavailable, long - acting dipeptidyl peptidase IV inhibitor in streptozotocin - induced diabetic peripheral neuropathy. J Pharmacol Exp Ther2012; 340: 64–72.
[90] Enoki Y, Watanabe H, Arake R, Fujimura R, Ishiodori K, Imafuku T, et al. Potential therapeutic interventions for chronic kidney disease - associated sarcopenia via indoxyl sulfate - induced mitochondrial dysfunction. J Cachexia Sarcopenia Muscle 2017; 8: 735–747.
[91] Giannocco G, Oliveira KC, Crajoinas RO, Venturini G, Salles TA, Fonseca - Alaniz MH, et al. Dipeptidyl peptidase IV inhibition upregulates GLUT4 translocation and expression in heart and skeletal muscle of spontaneously hypertensive rats. Eur J Pharmacol2013; 698: 74–86.
[92] Hoffmann P, Martin L, Keselica M, Gunson D, Skuba E, Lapadula D, et al. Acute toxicity of vildagliptin. ToxicolPathol2017; 45: 76–83.
[93] Wu T, Little TJ, Bound MJ, Borg M, Zhang X, Deacon CF, et al. A protein preload enhances the glucose - lowering efficacy of vildagliptin in type 2 diabetes. Diabetes Care 2016; 39: 511–517.
[94] Flock G, Baggio LL, Longuet C, Drucker DJ. Incretin receptors for glucagon - like peptide 1 and glucose - dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes 2007; 56: 3006–3013.
[95] Raun K, von Voss P, Gotfredsen CF, Golozoubova V, Rolin B, Knudsen LB. Liraglutide, a long - acting glucagon - like peptide - 1 analog, reduces body weight and food intake in obese candy - fed rats, whereas a dipeptidyl peptidase - IV inhibitor, vildagliptin, does not. Diabetes 2007; 56: 8–15.
[96] Scheen AJ. Sodium - glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2020; 16: 556–577.
[97] Ridderstrale M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC. Comparison of empagliflozin and glimepiride as add - on to metformin in patients with type 2 diabetes: a 104 - week randomised, active - controlled, double - blind, phase 3 trial. Lancet Diabetes Endocrinol 2014; 2: 691–700.
[98] Bolinder J, Ljunggren O, Johansson L, Wilding J, Langkilde AM, Sjostrom CD, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes ObesMetab2014; 16: 159–169.
[99] Blonde L, Stenlof K, Fung A, Xie J, Canovatchel W, Meininger G. Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgrad Med 2016; 128: 371–380.
[100] Bolinder J, Ljunggren O, Kullberg J, Johansson L, Wilding J, Langkilde AM, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab2012; 97: 1020–1031.
[101] Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATASU): 52 week results from a randomised,

double - blind, phase 3 non - inferiority trial. Lancet 2013; 382: 941–950.
[102] Nagai Y, Fukuda H, Kawanabe S, Nakagawa T, Ohta A, Tanaka Y. Differing effect of the sodium - glucose cotransporter 2 inhibitor ipragliflozin on the decrease of fat mass vs. lean mass in patients with or without metformin therapy. J Clin Med Res 2019; 11: 297–300.
[103] Koike Y, Shirabe SI, Maeda H, Yoshimoto A, Arai K, Kumakura A, et al. Effect of canagliflozin on the overall clinical state including insulin resistance in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract2019; 149: 140–146.
[104] Lundkvist P, Sjostrom CD, Amini S, Pereira MJ, Johnsson E, Eriksson JW. Dapagliflozin once - daily and exenatide once - weekly dual therapy: a 24 - week randomized, placebo - controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes. Diabetes ObesMetab2017; 19: 49–60.
[105] Sasaki T, Sugawara M, Fukuda M. Sodiumglucose cotransporter 2 inhibitor - induced changes in body composition and simultaneous changes in metabolic profile: 52 - week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study. J Diabetes Investig2019; 10: 108–117.
[106] Suzuki M, Takeda M, Kito A, Fukazawa M, Yata T, Yamamoto M, et al. Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models. Nutr Diabetes 2014; 4: e125.
[107] Naznin F, Sakoda H, Okada T, Tsubouchi H, Waise TM, Arakawa K, et al. Canagliflozin, a sodium glucose cotransporter 2 inhibitor, attenuates obesity - induced inflammation in the nodose ganglion, hypothalamus, and skeletal muscle of mice. Eur J Pharmacol2017; 794: 37–44.
[108] Jackuliak P, Kuzma M, Payer J. Effect of antidiabetic treatment on bone. Physiol Res 2019; 68: S107–S120.
[109] Schork A, Saynisch J, Vosseler A, Jaghutriz BA, Heyne N, Peter A, et al. Effect of SGLT2 inhibitors on body composition, fluid status and renin - angiotensin - aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy. Cardiovasc Diabetol2019; 18: 46.
[110] Tobita H, Sato S, Miyake T, Ishihara S, Kinoshita Y. Effects of dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type 2 diabetes mellitus: a prospective, open - label, uncontrolled study. CurrTher Res Clin Exp 2017; 87: 13–19.
[111] Yamamoto C, Miyoshi H, Ono K, Sugawara H, Kameda R, Ichiyama M, et al. Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy. Endocr J 2016; 63: 589–596.
[112] Seino Y, Yabe D, Sasaki T, Fukatsu A, Imazeki H, Ochiai H, et al. Sodium - glucose cotransporter - 2 inhibitor luseogliflozin added to glucagon - like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: a 52 - week, open - label, singlearm study. J Diabetes Investig2018; 9: 332–340.
[113] Yokono M, Takasu T, Hayashizaki Y, Mitsuoka K, Kihara R, Muramatsu Y, et al. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high - fat diet - induced obese rats. Eur J Pharmacol2014; 727: 66–74
[114] Age Ageing 2009, 38, 390–396. [CrossRef] 61. Dent, E.; Martin, F. C.; Bergman, H.; Woo, J.; Romero - Ortuno, R.; Walston, J. D. Management of frailty: Opportunities, challenges, and future directions. Lancet 2019, 394, 1376–1386.
[115] Bauer, J.; Morley, J. E.; Schols, A. M. W. J.; Ferrucci, L.; Cruz - Jentoft, A. J.; Dent, E.; Baracos, V. E.; Crawford, J. A.; Doehner, W.; Heymsfield, S. B.; et al. Sarcopenia: A Time for Action. An SCWD Position Paper. J. Cachexia Sarcopenia Muscle 2019, 10, 956–961.
[116] Wu, C. - N.; Tien, K. - J. The Impact of Antidiabetic Agents on Sarcopenia in Type 2 Diabetes: A Literature Review. J. Diabetes Res.2020, 2020, 9368583.
[117] Ito, H.; Ohno, Y.; Yamauchi, T.; Kawabata, Y.; Ikegami, H. Efficacy and safety of metformin for treatment of type 2 diabetes in elderly Japanese patients. Geriatr. Gerontol. Int.2011, 11, 55–62. [CrossRef]
[118] Aroda, V. R.; Edelstein, S. L.; Goldberg, R. B.; Knowler, W. C.; Marcovina, S. M.; Orchard, T.; Bray, G. A.; Schade, D. S.; Temprosa, M. G.; White, N. H.; et al. Long - term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. J. Clin. Endocrinol. Metab.2016, 101, 1754–1761
[119] Massimino, E.; Izzo, A.; Riccardi, G.; Della Pepa, G. The Impact of Glucose - Lowering Drugs on Sarcopenia in Type 2 Diabetes: Current Evidence and Underlying Mechanisms. Cells 2021, 10, 1958.
[120] Aghili, R.; Malek, M.; Valojerdi, A. E.; Banazadeh, Z.; Najafi, L.; Khamseh, M. E. Body composition in adults with newly diagnosed type 2 diabetes: Effects of metformin. J. Diabetes Metab. Disord.2014, 13, 88. [CrossRef] [PubMed]
[121] Baskaran, D.; Aparicio - Ugarriza, R.; Ferri - Guerra, J.; Milyani, R.; Florez, H.; Ruiz, J. G. Is There an Association Between Metformin Exposure and Frailty? Gerontol. Geriatr. Med.2020, 6, 2333721420924956. [CrossRef]
[122] Piskovatska, V.; Stefanyshyn, N.; Storey, K. B.; Vaiserman, A. M.; Lushchak, O. Metformin as a geroprotector: Experimental and clinical evidence. Biogerontology 2019, 20, 33–48.
[123] UK Prospective Diabetes Study (UKPDS) Group. Intensive blood - glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352, 837–853, Erratum in Lancet 1999, 354, 602.
[124] Cetrone, M.; Mele, A.; Tricarico, M. Effects of the antidiabetic drugs on the age - related atrophy and sarcopenia associated with diabetes type II. Curr. Diabetes Rev.2014, 10, 231–237.

[125] Mele, A.; Calzolaro, S.; Cannone, G.; Cetrone, M.; Conte, D.; Tricarico, D. Database search of spontaneous reports and pharmacological investigations on the sulfonylureas and glinides - induced atrophy in skeletal muscle. Pharmacol. Res. Perspect.2014, 2, e00028. [CrossRef]
[126] Strain, W. D.; Down, S.; Brown, P.; Puttanna, A.; Sinclair, A. Diabetes and Frailty: An Expert Consensus Statement on the Management of Older Adults with Type 2 Diabetes. Diabetes Ther.2021, 12, 1227–1247.
[127] Tao, Y.; Shi, J.; Zhang, Z. Sulfonylureas use and fractures risk in elderly patients with type 2 diabetes mellitus: A meta - analysis study. Aging Clin. Exp. Res.2021, 33, 2133–2139.
[128] Jojima, T.; Aso, Y. Attention to the use of oral anti - diabetic medication in older adults with type 2 diabetes. Nihon Rinsho. Jpn. J. Clin. Med.2013, 71, 1987–1992.
[129] Abbatecola, A. M.; Olivieri, F.; Corsonello, A.; Strollo, F.; Fumagalli, A.; Lattanzio, F. Frailty and safety: The example of diabetes. Drug Saf.2012, 35 (Suppl.1), 63–71.
[130] Erdmann, E.; Charbonnel, B.; Wilcox, R. G.; Skene, A. M.; Massi - Benedetti, M.; Yates, J.; Tan, M.; Spanheimer, R.; Standl, E.; Dormandy, J. A. PROactive Investigators. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: Data from the PROactive study (PROactive 08). Diabetes Care 2007, 30, 2773–2778.
[131] Loke, Y. K.; Singh, S.; Furberg, C. D. Long - term use of thiazolidinediones and fractures in type 2 diabetes: A meta - analysis. Can. Med Assoc. J.2009, 180, 32–39.
[132] Yokota, T.; Kinugawa, S.; Hirabayashi, K.; Suga, T.; Takada, S.; Omokawa, M.; Kadoguchi, T.; Takahashi, M.; Fukushima, A.; Matsushima, S.; et al. Pioglitazone improves whole - body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome. J. Diabetes Investig.2017, 8, 535–541.
[133] Starner, C. I.; Schafer, J. A.; Heaton, A. H.; Gleason, P. P. Rosiglitazone and Pioglitazone Utilization from January 2007 Through May 2008 Associated with Five Risk - Warning Events. J. Manag. Care Pharm.2008, 14, 523–531.
[134] Doucet, J.; Chacra, A.; Maheux, P.; Lu, J.; Harris, S.; Rosenstock, J. Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus. Curr. Med Res. Opin.2011, 27, 863–869.
[135] Formiga, F.; Vidal, X.; Agustí, A.; Chivite, D.; Rosón, B.; Barbé, J.; López - Soto, A.; Torres, O. H.; Fernández - Moyano, A.; García, J.; et al. Potentially Inappropriate Prescription in Older Patients in Spain (PIPOPS) Investigators' Project. Inappropriate prescribing in elderly people with diabetes admitted to hospital. Diabet. Med.2016, 33, 655–662.
[136] Sposito, A. C.; Berwanger, O.; de Carvalho, L. S. F.; Saraiva, J. F. K. GLP - 1Ras in type 2 diabetes: Mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data. Cardiovasc. Diabetol.2018, 17, 157.
[137] Nusca, A.; Tuccinardi, D.; Pieralice, S.; Giannone, S.; Carpenito, M.; Monte, L.; Watanabe, M.; Cavallari, I.; Maddaloni, E.; Ussia, G. P.; et al. Platelet Effects of Anti - diabetic Therapies: New Perspectives in the Management of Patients with Diabetes and Cardiovascular Disease. Front. Pharmacol.2021, 12, 670155.
[138] Linnebjerg, H.; Kothare, P. A.; Seger, M.; Wolka, A. M.; Mitchell, M. I. Exenatide—Pharmacokinetics, pharmacodynamics, safety and tolerability in patients ≥ 75 years of age with Type 2 diabetes. Int. J. Clin. Pharmacol. Ther.2011, 49, 99–108.
[139] American Diabetes Association Professional Practice Committee.10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022. Diabetes Care 2022, 45 (Suppl.1), S144–S174.
[140] Palmiero, G.; Cesaro, A.; Vetrano, E.; Pafundi, P.; Galiero, R.; Caturano, A.; Moscarella, E.; Gragnano, F.; Salvatore, T.; Rinaldi, L.; et al. Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects. Int. J. Mol. Sci.2021, 22, 5863.
[141] Hartman, R. E.; Rao, P.; Churchwell, M. D.; Lewis, S. J. Novel therapeutic agents for the treatment of diabetic kidney disease. Expert Opin. Investig. Drugs 2020, 29, 1277–1293.
[142] Custódio, J. S., Jr.; Roriz - Filho, J.; Cavalcanti, C. A. J.; Martins, A.; Salles, J. E. N. Use of SGLT2 Inhibitors in Older Adults: Scientific Evidence and Practical Aspects. Drugs Aging 2020, 37, 399–409.
[143] Sinclair, A. J.; Bode, B.; Harris, S.; Vijapurkar, U.; Shaw, W.; Desai, M.; Meininger, G. Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis. J. Am. Geriatr. Soc.2016, 64, 543–552.
[144] Gannon, J.; Claffey, P.; Laird, E.; Newman, L.; Kenny, R.; Briggs, R. The cross - sectional association between diabetes and orthostatic hypotension in community - dwelling older people. Diabet. Med.2020, 37, 1299–1307.
[145] Umegaki, H. Sarcopenia and frailty in older patients with diabetes mellitus. Geriatr. Gerontol. Int.2016, 16, 293–299.
[146] Janka, H. U. Insulin therapy in elderly patients with type 2 diabetes: The role of insulin glargine. Diabetes Obes. Metab.2008, 10, 35–41.
[147] Yang, Y.; Hu, X.; Zhang, Q.; Zou, R. Diabetes mellitus and risk of falls in older adults: A systematic review and meta - analysis. Age Ageing 2016, 45, 761–767.
[148] Fanzani, A.; Conraads, V. M.; Penna, F.; Martinet, W. Molecular and cellular mechanisms of skeletal muscle atrophy: An update. J. Cachex - Sarcopenia Muscle 2012, 3, 163–179.
[149] Carrascosa, J. M.; Andrés, A.; Ros, M.; Bogónez, E.; Arribas, C.; Fernández - Agulló, T.; De Solis, A. J.; Gallardo, N.; Martínez, C. Development of insulin resistance during aging: Involvement of central processes and role of adipokines. Curr. Protein Pept. Sci.2011, 12, 305–315.